SynthesisInternational dental journal2026
The Efficacy of Mesenchymal Stem Cell-Based Therapy for Sjögren's Syndrome: A Systematic Review and Meta-Analysis of Preclinical Studies.
Synthesis in International dental journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSjögren's syndrome (SjS) is a chronic autoimmune disease primarily characterized by xerostomia, often accompanied by xerophthalmia, cutaneous dryness, arthralgia, and stiffness. Mesenchymal stem cell (MSC)-based therapies have shown promising immunomodulatory potential in autoimmune diseases, yet their efficacy in SjS remains uncertain. Before advancing to clinical application, a systematic evaluation of preclinical evidence is essential to clarify their therapeutic impact and experimental consistency.
methodsThis systematic review and meta-analysis were registered in PROSPERO (CRD42023471348) and conducted in accordance with PRISMA guidelines. Comprehensive searches were performed in PubMed, Embase, Scopus, Cochrane Library, and Web of Science up to 1 May 2025. Random-effects meta-analyses were conducted to assess changes in salivary flow rate (SFR), inflammatory infiltration, and cytokine expression.
resultsA total of 25 studies met the inclusion criteria. Pooled analyses demonstrated that MSCs, MSC-derived exosomes, and MSC-conditioned medium significantly improved stimulated SFR (standardized mean difference = 3.19, 95% confidence interval 2.50-3.88, P < .001) and reduced inflammatory infiltration (standardized mean difference = -2.04, 95% confidence interval -2.66 to -1.43, P < .001). MSC-based therapies decreased serum levels of proinflammatory cytokines (interleukin-6 [IL-6] and interferon-gamma) and increased IL-10. Exploration of heterogeneity indicated that MSC type and dosage influenced SFR outcomes, MSC intervention type affected inflammatory infiltration and serum IL-6 levels, and MSC dosage influenced serum IL-10 levels.
conclusionMSC-based therapies show potential for treating SjS in animal models, improving salivary secretion, reducing inflammation, and modulating immune cytokines. Substantial heterogeneity across studies highlights the need for standardized protocols regarding MSC source, dosage, and treatment duration before clinical translation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.